Nothing Special   »   [go: up one dir, main page]

SK133897A3 - Combination compositions containing benazepril or benazeprilat and valsartan - Google Patents

Combination compositions containing benazepril or benazeprilat and valsartan Download PDF

Info

Publication number
SK133897A3
SK133897A3 SK1338-97A SK133897A SK133897A3 SK 133897 A3 SK133897 A3 SK 133897A3 SK 133897 A SK133897 A SK 133897A SK 133897 A3 SK133897 A3 SK 133897A3
Authority
SK
Slovakia
Prior art keywords
active ingredient
valsartan
composition according
benazeprilat
benazepril
Prior art date
Application number
SK1338-97A
Other languages
English (en)
Slovak (sk)
Inventor
Gasparo Marc De
Randy L Webb
David S Cohen
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of SK133897A3 publication Critical patent/SK133897A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1338-97A 1995-04-07 1996-04-02 Combination compositions containing benazepril or benazeprilat and valsartan SK133897A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH101295 1995-04-07
PCT/EP1996/001440 WO1996031234A1 (en) 1995-04-07 1996-04-02 Combination compositions containing benazepril or benazeprilat and valsartan

Publications (1)

Publication Number Publication Date
SK133897A3 true SK133897A3 (en) 1998-02-04

Family

ID=4200393

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1338-97A SK133897A3 (en) 1995-04-07 1996-04-02 Combination compositions containing benazepril or benazeprilat and valsartan

Country Status (15)

Country Link
EP (1) EP0820302A1 (ja)
JP (1) JPH11503139A (ja)
KR (1) KR19980703647A (ja)
CN (1) CN1181019A (ja)
AU (1) AU5399096A (ja)
BR (1) BR9604818A (ja)
CA (1) CA2214143A1 (ja)
CZ (1) CZ313897A3 (ja)
HU (1) HUP9801593A2 (ja)
MX (1) MX9707683A (ja)
NO (1) NO974400D0 (ja)
PL (1) PL322529A1 (ja)
SK (1) SK133897A3 (ja)
TR (1) TR199701121T1 (ja)
WO (1) WO1996031234A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835106A4 (en) * 1995-06-30 1998-09-30 Merck & Co Inc METHOD FOR TREATING KIDNEY DISEASES USING AN ACE INHIBITOR AND AII ANTAGONIST
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
MXPA02010090A (es) * 2000-04-12 2003-02-12 Novartis Ag Combinacion de al menos dos compuestos seleccionados de los grupos de un antagonista del receptor at-1 o un inhibidor ace o un inhibidor de la hmg-co-a reductasa.
AU2001289672B2 (en) * 2000-07-19 2005-12-08 Novartis Ag Valsartan salts
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
HUP0303836A2 (hu) * 2000-08-22 2004-04-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Angiotenzin antagonisták és ACE inhibitorok gyógyszerészeti kombinációja és ezeket tartalmazó gyógyszerkészítmények
CA2432638A1 (en) * 2000-12-18 2002-06-27 Novartis Ag Therapeutic combination of amlodipine and benazepril
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
CN100377744C (zh) * 2002-07-05 2008-04-02 安徽省生物医学研究所 一种预测acei类降压药药效的复方药
US20050272649A1 (en) * 2002-08-28 2005-12-08 Hruska Keith A Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CN101869710A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 降压药物组合物
SG176585A1 (en) 2009-05-20 2012-01-30 Boehringer Ingelheim Vetmed Pharmaceutical oral telmisartan solution
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN105939728A (zh) * 2014-01-31 2016-09-14 詹森药业有限公司 用于治疗和预防肾病和脂肪肝病的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0527879T3 (da) * 1990-05-11 1997-07-14 Pfizer Synergistiske terapeutiske præparater og fremgangsmåder.
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists

Also Published As

Publication number Publication date
NO974400L (no) 1997-09-23
CZ313897A3 (cs) 1998-01-14
KR19980703647A (ko) 1998-12-05
EP0820302A1 (en) 1998-01-28
CA2214143A1 (en) 1996-10-10
BR9604818A (pt) 1998-06-09
TR199701121T1 (xx) 1998-03-21
MX9707683A (es) 1997-12-31
JPH11503139A (ja) 1999-03-23
CN1181019A (zh) 1998-05-06
NO974400D0 (no) 1997-09-23
WO1996031234A1 (en) 1996-10-10
HUP9801593A2 (hu) 1999-01-28
PL322529A1 (en) 1998-02-02
AU5399096A (en) 1996-10-23

Similar Documents

Publication Publication Date Title
CA2678722C (en) Antihypertensive combination of valsartan and a calcium channel blocker
EP1467728B1 (en) Pharmaceutical compositions comprising valsartan and nep inhibitors
US6395728B2 (en) Method of treatment and pharmaceutical composition
SK133897A3 (en) Combination compositions containing benazepril or benazeprilat and valsartan
US8404744B2 (en) Methods of treatment and pharmaceutical composition
RU2316318C2 (ru) Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик
US6204281B1 (en) Method of treatment and pharmaceutical composition
WO2007106708A2 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
US6767905B2 (en) Use of angiotensin II receptor antagonists for treating acute myocardial infarction
US20020193562A1 (en) Hydroxamic acid containing compounds useful as ace inhibitors and / or nep inhibitors
WO2005039637A2 (en) Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker
CZ227092A3 (en) Pharmaceutical composition used in high blood pressure therapy
AU2003200032B2 (en) Method of treatment and pharmaceutical composition
US20180311241A1 (en) Pharmaceutical synergistic combination
AU2006202999A1 (en) Pharmaceutical compositions comprising valsartan and NEP inhibitors
MXPA01000322A (en) Method of treatment and pharmaceutical composition
WO2004075893A1 (en) Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker